$0.4179
-0.02-5.35%
At close: -
$0.4264
0.008502.03%
After Hours: 5:06 PM EDT
Comments
Loading...
CARISMA Therapeutics (CARM) Forecast
NewsEarningsCARISMA Therapeutics (CARM) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestCARISMA Therapeutics (NASDAQ:CARM) Stock Quotes, Forecast and News Summary
CARISMA Therapeutics Stock (NASDAQ: CARM) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy CARISMA Therapeutics (CARM) stock?
You can purchase shares of CARISMA Therapeutics (NASDAQ:CARM) through any online brokerage.
Who are CARISMA Therapeutics (CARM) competitors?
Other companies in CARISMA Therapeutics’s space includes: NKGen Biotech (NASDAQ:NKGN), Nanoviricides (AMEX:NNVC), Bolt Biotherapeutics (NASDAQ:BOLT), Geovax Labs (NASDAQ:GOVX) and Palatin Techs (AMEX:PTN).
What is the forecast, or price target, for CARISMA Therapeutics (CARM) stock?
CARISMA Therapeutics has a consensus price target of $9.54.
What is the current price for CARISMA Therapeutics (CARM)?
The stock price for CARISMA Therapeutics (NASDAQ: CARM) is $0.4264 last updated December 20, 2024 at 5:06 PM EST.
Does CARISMA Therapeutics (CARM) pay a dividend?
There are no upcoming dividends for CARISMA Therapeutics.
When is CARISMA Therapeutics (NASDAQ:CARM) reporting earnings?
CARISMA Therapeutics’s Q3 earnings are confirmed for Thursday, November 7, 2024.
Is CARISMA Therapeutics (CARM) going to split?
There is no upcoming split for CARISMA Therapeutics.
What sector and industry does CARISMA Therapeutics (CARM) operate in?
CARISMA Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.